Contact us via E-Mail
Follow us on LinkedInAll-time Popular Posts
A biobetter trastuzumab is on the way 
EGA president calls on Member States to boost market access for biosimilars in the EU 
3rd Forum on Biosimilars 
Pfizer starts biosimilar rituximab Phase I/II trial 
Indian Biosimilars Market 
World’s first biosimilar antibody* is approved in Korea 
A biosimilar manufacturer: Celltrion 
2 patents down, 1 to expire: Herceptin biosimilar coming to EU
Post Tagged with: "EMA"
March 10, 2017 1:08 PM
EBE, EFPIA and IFPMA have today launched a position paper entitled “Considerations for physicians on switching decisions regarding biosimilars”
February 24, 2017 9:17 AM
Mundipharma to launch Truxima, the first rituximab biosimilar in seven European markets
January 20, 2017 6:35 AM
Boehringer Ingelheim biosimilar candidate to Humira accepted for review by EMA and FDA
December 27, 2016 11:47 AM
Tailored scientific advice to support step-by-step development of new biosimilars in EU
